U.S. markets closed
  • S&P Futures

    3,319.00
    -14.75 (-0.44%)
     
  • Dow Futures

    27,283.00
    -125.00 (-0.46%)
     
  • Nasdaq Futures

    11,286.75
    -51.00 (-0.45%)
     
  • Russell 2000 Futures

    1,499.30
    -7.70 (-0.51%)
     
  • Crude Oil

    38.92
    -0.37 (-0.94%)
     
  • Gold

    1,895.10
    -8.10 (-0.43%)
     
  • Silver

    24.01
    -0.43 (-1.76%)
     
  • EUR/USD

    1.1732
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    0.6450
    -0.0180 (-2.71%)
     
  • Vix

    26.27
    +0.08 (+0.31%)
     
  • GBP/USD

    1.2839
    -0.0021 (-0.16%)
     
  • USD/JPY

    105.5900
    -0.0650 (-0.06%)
     
  • BTC-USD

    10,781.34
    -62.87 (-0.58%)
     
  • CMC Crypto 200

    231.00
    +1.33 (+0.58%)
     
  • FTSE 100

    5,897.50
    -30.43 (-0.51%)
     
  • Nikkei 225

    23,509.77
    -29.33 (-0.12%)
     

Applied DNA to initiate clinical trial of Covid-19 vaccine for cats

Sept 16 (Reuters) - Applied DNA Sciences plans to initiate clinical trial of one of its five LineaDNA vaccine candidates for veterinary use to prevent coronavirus infections in domestic cats, the diagnostic test maker said on Wednesday.

The trials will be conducted in collaboration with biotechnology firm Evvivax S.R.L. on receiving approval from the U.S. Department of Agriculture, Applied DNA said in a statement.

The study will evaluate domestic feline immune response, safety and tolerability of the vaccine candidate and determine evidence of antibody and T-cell response in them.

The trial intends to enroll 30 healthy domestic felines and follow them for six months.

Earlier in July, Applied DNA said five of its LineaDNA vaccine candidates showed strong antibody responses at low doses in mice studies. (Reporting by Aishwarya Nair in Bengaluru; Editing by Anil D'Silva)